Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
about
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyEarly Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.Antibody-secreting plasma cells persist for decades in human intestine.To B or not to B maintained?Recurrent urinary tract infections and low secretory IgA following CD19-directed CAR T-cell therapy for relapsed acute lymphoblastic leukemia.Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.Plasma cell survival in the absence of B cell memory.Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in Multiple Myeloma.The Pharmacology of T Cell Therapies.Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus.B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
P2860
Q28080304-6066B8F1-460F-4C55-8377-C74C6782A240Q33762211-0ABC32E8-6AC3-4145-A6BD-06F1163D7460Q37706835-46404CAA-5452-47F3-AF49-B7E03B15596EQ39032901-0CCDE5A8-8710-460D-B4EA-3D3DF50E22ECQ39106490-37377533-F647-4F55-870B-29C001C14C15Q40364936-076D53CE-791E-4F73-B630-1794E0B2C131Q41868773-D403A4D6-2A74-4CCE-901F-8FDD492E608DQ43806662-05E3FF9E-97A7-4B3B-A774-ABD19EB64B94Q45871879-08889374-81FD-4667-9546-1011ABB69F3EQ47113778-0683AE6E-5DFD-48DC-843A-B8DB836A15B8Q47443955-33DC72DA-307D-4FFC-BF85-8B2F68FC1844Q47820469-75C95FAA-0F2E-4DAB-9873-6094EED997F7Q48334966-A4A44642-8CF4-43E0-88E0-AE624F74177DQ54985631-A58513C9-51C8-4C56-8A8C-D74471F344B2Q55266542-4B7BBD26-E88E-4EC8-8EC3-F58C4D84D170Q55283579-C47E475C-A5F4-40B9-B184-2D1629EDC3DBQ55445399-43C46762-7ADD-4500-A735-F158213E5C9D
P2860
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 May 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistence of long-lived plas ...... 19-directed CAR T-cell therapy
@en
Persistence of long-lived plas ...... 9-directed CAR T-cell therapy.
@nl
type
label
Persistence of long-lived plas ...... 19-directed CAR T-cell therapy
@en
Persistence of long-lived plas ...... 9-directed CAR T-cell therapy.
@nl
prefLabel
Persistence of long-lived plas ...... 19-directed CAR T-cell therapy
@en
Persistence of long-lived plas ...... 9-directed CAR T-cell therapy.
@nl
P2093
P2860
P50
P1433
P1476
Persistence of long-lived plas ...... 19-directed CAR T-cell therapy
@en
P2093
Amrom E Obstfeld
Carl H June
Christoph T Ellebrecht
Colleen A Callahan
David L Porter
Dimitrios Arhontoulis
Farzana Nazimuddin
Gerald Wertheim
James Capobianchi
P2860
P304
P356
10.1182/BLOOD-2016-01-694356
P407
P577
2016-05-10T00:00:00Z